Overview
CGRP (Calcitonin Gene-Related Peptide) is a 37-amino acid neuropeptide produced by alternative splicing of the calcitonin gene. It is one of the most potent endogenous vasodilators known and plays a central role in migraine pathophysiology, nociception, and cardiovascular regulation. Two isoforms exist: α-CGRP (neuronal) and β-CGRP (enteric).
Mechanism of action
CGRP binds to the CLR/RAMP1 receptor complex (CGRP receptor), activating adenylyl cyclase and increasing intracellular cAMP. This triggers smooth muscle relaxation and potent vasodilation, particularly in cranial blood vessels. During migraine, CGRP is released from trigeminal nerve terminals, activating the trigeminovascular system and promoting neurogenic inflammation and peripheral sensitization. Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) and CGRP receptor antagonists (gepants) block this cascade.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| vasodilation research (in vitro/animal) | intravenous | 0.1–10 nmol/kg | single dose per experiment | |
| nociception model (animal) | subcutaneous | 1–100 nmol | per experimental protocol |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
CGRP's role in migraine is among the best-validated therapeutic targets in pain neuroscience. Plasma CGRP levels rise during spontaneous migraine attacks and normalize with triptan treatment. Multiple FDA-approved drugs targeting CGRP or its receptor have demonstrated efficacy in migraine prevention and acute treatment. Preclinical studies show CGRP also regulates bone metabolism, wound healing, and cardiac function. Research-use peptide is employed in vasodilation and nociception models.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Legal status
Endogenous CGRP peptide is available for research use only. Therapeutic monoclonal antibodies targeting CGRP/its receptor (erenumab, fremanezumab, galcanezumab) are FDA-approved prescription medications. The raw peptide is not approved for human administration.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.